Patterns of managing chronic hepatitis B treatment-related drug resistance: A survey of physicians in Mainland China, South Korea, Taiwan, and Thailand

Hepatology International

Volumn 3, Issue 3, 2009, Pages 453-460

  Chainuvati, Siwaporn ^a   Cheng, Jun ^b   Hou, Jin Lin ^c   Hsu, Chao Wei ^d   Jia, Ji Dong ^e   Komolmit, Piyawat ^f   Kwon, So Young ^g   Lee, Chang Hong ^g   Li, Hong ^h   Li, Ying ^h   Liu, Chun Jen ⁱ   Neo, Boon Leong ^h   Peng, Cheng Yuan ^j   Tanwandee, Tawesak ^k   Wongcharatrawee, Suchat ^h   Wu, Jaw Ching ^l   Yu, Ming Lung ^m,n   Zhang, Xin Xin ^o  

^a MAHIDOL UNIVERSITY   (Thailand)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f CHULALONGKORN UNIVERSITY   (Thailand)

^g Konkuk University School of Medicine   (South Korea)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^j CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^k MAHIDOL UNIVERSITY   (Thailand)

^l TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^m KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁿ KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^o SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

more..

Author keywords

ALT; Antiviral resistance; Asia; Chronic hepatitis B; HBV DNA; Nucleoside nucleotide analogs

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ENTECAVIR; INTERFERON; LAMIVUDINE; VIRUS DNA;

ADD ON THERAPY; ARTICLE; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST OF ILLNESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEALTH SURVEY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MANAGED CARE; PATIENT MONITORING; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SOUTH KOREA; TAIWAN; THAILAND;

EID: 68949158471     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-009-9139-9     Document Type: Article

References (19)

1. Chen G, Lin W, Shen FM, IIoeje UH, London T, Evans AA. Chronic hepatitis B virus infection and mortality from non-liver causes: Results from the Haimen City cohort study. Int J Epidemiol 2005;34:132-137
2. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73
3. Iloeje UH, Yang HY, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;30:678-686
4. Lok AS, McMahon BJ. AASLD practice guidelines on chronic hepatitis B. Hepatology 2007;45:507-539
5. Liaw YF, Sung JJY, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531
6. Keeffe EB, Dieterich DT, Han SB, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6:1315-1341
7. Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int 2008;2:163-178
8. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asia-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int 2008;2:263-283
9. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology 2007;46:254-265
10. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B. J Hepatol 2009;50:227-242
11. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005;42:1414-1419
12. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008;2:147-151
13. Pawlotsky JM, Dusheis G, Hatzakis A, Lau D, Lau G, Liang TJ, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: Recommendations for a standardized approach. Gastroenterology 2008;134:405-415
14. Li SC, Ong SC, Lim SG, Yeoh KG, Kwong KS, Lee V, et al. A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore. J Clin Gastroenterol 2004;38(Suppl 3):S136-S143
15. Hsieh CR, Kuo CW. Cost of chronic hepatitis B virus infection in Taiwan. J Clin Gastroenterol 2004;38(Suppl 3):S148-S152
16. Guan ZQ, Dong ZH, Wang QH, Cao DX, Fang YY, Liu HT, et al. Cost of chronic hepatitis B infection in Mainland China. J Clin Gastroenterol 2004;38(Suppl 3):S175-S178
17. Yang BM, Kim CH, Kim JY. Cost of chronic hepatitis B infection in South Korea. J Clin Gastroenterol 2004;38(Suppl 3):S153-S157
18. Lesmana LA, Leung NWY, Mahachai V, Phiet PH, Suh DJ, Yao GB, et al. Hepatitis B: Overview of the burden of disease in the Asia-Pacific region. Liver Int 2006;26:3-10
19. Tafesse E, Claxton A, Granger A, Sanders J, Apelian D, Atillasoy E, et al. Estimates of health care costs for lamivudine-refractory chronic hepatitis B (CHB) patients. In Proceedings of the ISPOR 10th annual international meeting; 15-18 May 2005; Washington, DC